提高投资者回报 研发管线潜在价值凸显 根据公司业绩快报，公司全年实现基本每股收益0.74元，同比增长15.63%，实现企业对投资者回报的提 高。 本报讯 （记者袁传玺）天士力2025年加入华润体系后首年融合业绩超出市场预期。2月6日晚间，天士 力发布的2025年业绩快报显示，公司2025年实现营业总收入82.36亿元；实现归属于上市公司股东的净 利润11.05亿元，同比增加15.68%。 融入华润体系推动提质增效 据悉，天士力作为华润三九"一体两翼"战略中的"一翼"，核心定位为"创新驱动"。天士力正全面推进与 华润三九的首年融合工作，从"价值重塑"、"业务重塑"、"组织重塑"和"精神重塑"四个维度系统化升级 管理体系，实现强强联合的战略协同。 公司在融入华润体系的同时，进行组织和运营管理等各个方面的优化，逐步提升公司经营资产的质量。 申万宏源证券的研报指出，华润三九将借助其在管理、渠道、产业方面的资源，为公司进一步赋能，促 进协同效应，提升天士力的竞争优势。在运营管理方面，公司积极落实华润管理理念，加强财务、人力 资源、EHSQ及大监督体系的融合，开展"焕新增效"等系列组织优化活动，优化运营管控模式，提升管 ...

Core Viewpoint - Tianjin Tasly Pharmaceutical Group Co., Ltd. reported a net profit of 775 million yuan for the first half of 2025, marking a year-on-year increase of 16.97%, indicating steady improvement in operational performance and quality [1] Financial Performance - The company achieved total revenue of 4.288 billion yuan in the first half of 2025, with pharmaceutical manufacturing revenue at 3.879 billion yuan, remaining stable compared to the same period last year, and pharmaceutical commercial revenue at 386 million yuan [1] - The net profit attributable to shareholders reached 775 million yuan, reflecting a year-on-year growth of 16.97% [1] - The asset-liability ratio decreased from 19.13% at the beginning of the year to 18.43% by the end of the reporting period, a reduction of 0.7 percentage points [1] - The company plans to distribute a cash dividend of 2.1 yuan per 10 shares (tax included) to all shareholders, amounting to approximately 313.73 million yuan, which represents 40.50% of the net profit attributable to shareholders for the first half of 2025 [1] Corporate Changes - In the first half of 2025, the controlling shareholder changed to China Resources Sanjiu, with the actual controller becoming China Resources Limited, officially integrating the company into the China Resources Sanjiu group [1] Strategic Initiatives - The company is actively implementing a "100-day integration" with China Resources Sanjiu, focusing on operational management, financial, human resources, and compliance systems integration to enhance management efficiency and lay a solid foundation for future business collaboration [2] - Strategic planning efforts include organizing multiple strategic integration discussions between the management teams of both companies, aiming to develop the "14th Five-Year" strategic plan to guide future growth and high-quality development [2] - In marketing, the company is collaborating with China Resources to enhance product market share through resource integration and establishing a cooperative mechanism for new product development [2] - The company plans to comprehensively advance the first-year integration work with China Resources Sanjiu, focusing on "value reshaping," "business reshaping," "organizational reshaping," and "spiritual reshaping" to systematically upgrade the management system [2]

Core Viewpoint - Tianjin Tasly Pharmaceutical Co., Ltd. reported a net profit of 775 million yuan for the first half of 2025, marking a year-on-year increase of 16.97%, indicating steady improvement in operational performance and quality [1] Financial Performance - The company achieved total revenue of 4.288 billion yuan in the first half of 2025, with pharmaceutical industrial revenue at 3.879 billion yuan, remaining stable compared to the same period last year, and pharmaceutical commercial revenue at 386 million yuan [1] - The net profit attributable to shareholders reached 775 million yuan, reflecting a year-on-year growth of 16.97% [1] - The asset-liability ratio decreased from 19.13% at the beginning of the year to 18.43% by the end of the reporting period, a reduction of 0.7 percentage points [1] - The company plans to distribute a cash dividend of 2.1 yuan per 10 shares (including tax), totaling approximately 313.73 million yuan, which represents 40.50% of the net profit attributable to shareholders for the first half of 2025 [1] Corporate Changes and Strategic Initiatives - In the first half of 2025, the controlling shareholder changed to China Resources Sanjiu, with the actual controller being China Resources Limited, marking the company's formal integration into the China Resources Sanjiu group [1] - The company is actively promoting the "100-day integration" with China Resources Sanjiu, focusing on operational management, financial integration, and organizational optimization to enhance management efficiency and lay a solid foundation for future business collaboration [2] - Strategic planning efforts include multiple discussions between the management teams of both companies to develop the "15th Five-Year Plan," aiming to guide future development and promote high-quality growth [2] - In marketing, the company is leveraging synergies with China Resources to enhance market cooperation for key products and establish collaborative mechanisms for new product development [2] - The company plans to comprehensively advance the first-year integration work with China Resources Sanjiu, focusing on "value reshaping," "business reshaping," "organizational reshaping," and "spiritual reshaping" to systematically upgrade the management system [2]